Melanoma of unknown primary: Favorable survival persists in the immunotherapy era.

被引：0
|
作者：
Maharaj, Satish [1 ]
Jain, Nikita [1 ]
Albawaliz, Anas [1 ]
Miller, Donald M. [1 ]
Chesney, Jason Alan [1 ]
机构：
[1] Brown Canc Ctr, Louisville, KY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21513
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Predictors of overall survival (OS) in patients (pts) with melanoma brain metastasis (MBM) in the modern era.
    Hasanov, Merve
    Milton, Denai R.
    Davies, Alicia Bea
    Sirmans, Elizabeth
    Saberian, Chantal M.
    Posada, Eliza
    Gershenwald, Jeffrey E.
    Torres-Cabala, Carlos A.
    Huse, Jason T.
    Tawbi, Hussein Abdul-Hassan
    Glitza, Isabella Claudia
    Li, Jing
    Chung, Caroline
    Yeboa, Debra
    Opusunju, Sylvia
    Kim, Betty Y. S.
    Lang, Frederick F.
    Haydu, Lauren Elaine
    Davies, Michael A.
    Ferguson, Sherise D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy
    Verver, Danielle
    Grunhagen, Dirk J.
    van Akkooi, Alexander C. J.
    Aarts, Maureen J. B.
    van den Berkmortel, Franchette W. P. J.
    van den Eertwegh, Alfonsus J. M.
    de Groot, Jan Willem B.
    Boers-Sonderen, Marye J.
    Haanen, John B. A. G.
    Hospers, Geke A. P.
    Kapiteijn, Ellen
    Piersma, Djura
    van Rijn, Rozemarijn S.
    Suijkerbuijk, Karijn P. M.
    Tije, Albert J. ten
    Vreugdenhil, Gerard
    Verhoef, Cornelis
    van der Veldt, Astrid A. M.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (11) : 3123 - 3135
  • [23] Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy
    Danielle Verver
    Dirk J. Grünhagen
    Alexander C. J. van Akkooi
    Maureen J. B. Aarts
    Franchette W. P. J. van den Berkmortel
    Alfonsus J. M. van den Eertwegh
    Jan Willem B. de Groot
    Marye J. Boers-Sonderen
    John B. A. G. Haanen
    Geke A. P. Hospers
    Ellen Kapiteijn
    Djura Piersma
    Rozemarijn S. van Rijn
    Karijn P. M. Suijkerbuijk
    Albert J.ten Tije
    Gerard Vreugdenhil
    Cornelis Verhoef
    Astrid A. M. van der Veldt
    Cancer Immunology, Immunotherapy, 2021, 70 : 3123 - 3135
  • [24] Improved survival for stage IV melanoma from an unknown primary site
    Lee, C. C.
    Faries, M. B.
    Wanek, L. A.
    Morton, D. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] Melanoma of Unknown Primary Origin: Decreased Survival for Stage 4 Patients
    Rushing, E. C.
    Tuthill, R.
    LABORATORY INVESTIGATION, 2011, 91 : 124A - 124A
  • [26] Improved Survival for Stage IV Melanoma From an Unknown Primary Site
    Lee, Chris C.
    Faries, Mark B.
    Wanek, Leslie A.
    Morton, Donald L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (21) : 3489 - 3495
  • [27] Is there an Overall Survival Different Between Patients with Known and Unknown Primary Melanoma?
    Wainstein, A.
    Bittencourt, F.
    Bretas, G.
    Cherobim, A.
    Santos, F.
    Wainstein, A.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 76 - 76
  • [28] Do stage III melanoma patients with melanoma of unknown primary have better survival than patients with melanoma of known primary?
    Rodgaard, J. C.
    Kjerkegaard, U.
    Sorensen, J. A.
    Stolle, L. B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 : 59 - 59
  • [29] Do stage IV melanoma patients with melanoma of unknown primary have better survival than patients with melanoma of known primary?
    Rodgaard, J. C.
    Kjerkegaard, U.
    Sorensen, J. A.
    Stolle, L. B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 : 60 - 60
  • [30] Survival after recurrence of medulloblastoma in the contemporary era.
    Koschmann, C.
    Schmidt, K. L.
    Geyer, J. R.
    Leary, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345